The Role of CTLA-4 in T Cell Exhaustion in Chronic Hepatitis B Virus Infection
Viruses, 2023 Patients with chronic hepatitis B (CHB) gradually develop T cell exhaustion, and the inhibitory receptor molecule, cytotoxic T-lymphocyte antigen-4 (CTLA-4), may play a role in this phenomenon.
Ása Didriksen Apol +4 more
doaj +1 more source
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]
, 2019 Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence +2 more
core +2 more sources
Tolerance without clonal expansion: Self-antigen-expressing B cells program self-reactive T cells for future deletion [PDF]
, 2008 B cells have been shown in various animal models to induce immunological tolerance leading to reduced immune responses and protection from autoimmunity.
Anderton, Stephen M. +9 more
core +1 more source
Arthritis Research & Therapy, 2020 Background Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) competes with CD28 for binding CD80/CD86 on antigen-presenting cells (APCs) to limit T cell activation.
Po-Chun Liu +7 more
doaj +1 more source
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources
A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect
Molecular Therapy: Nucleic Acids, 2017 The successful translation of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade has revolutionized the concept of cancer immunotherapy. Although monoclonal antibody therapeutics remain the mainstream in clinical practice, aptamers are synthetic ...
Bo-Tsang Huang +6 more
doaj +1 more source
A bispecific protein capable of engaging CTLA-4 and MHCII protects non-obese diabetic mice from autoimmune diabetes. [PDF]
PLoS ONE, 2013 Crosslinking ligand-engaged cytotoxic T lymphocyte antigen-4 (CTLA-4) to the T cell receptor (TCR) with a bispecific fusion protein (BsB) comprised of a mutant mouse CD80 and lymphocyte activation antigen-3 (LAG-3) has been shown to attenuate TCR ...
Hongmei Zhao +10 more
doaj +1 more source
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]
, 2017 Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello +3 more
core +1 more source
Immunity, 2023 Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous success treating B cell malignancies; however, some patients fail to respond due to poor autologous T cell fitness. To improve response rates, we investigated whether disruption of the co-inhibitory receptors CTLA4 or PD-1 could restore CART function.
Sangya Agarwal +19 more
openaire +2 more sources
Acquisition of pneumococci specific effector and regulatory Cd4+ T cells localising within human upper respiratory-tract mucosal lymphoid tissue [PDF]
, 2011 The upper respiratory tract mucosa is the location for commensal Streptococcus (S.) pneumoniae colonization and therefore represents a major site of contact between host and bacteria.
AD Reynolds +62 more
core +3 more sources